Pemetrexed Disodium [150399-23-8]

Walters CL, Arend RC, Armstrong DK, et al. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol. 2013 Nov;131(2):493-8. PMID: 23863359. Lau DH, Moon J, Davies AM, et al. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer. 2013 Jul;14(4):351-5. PMID: 23415808. Yang TY, Chang GC, Chen KC, et al. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. Mol Carcinog. 2013 Mar;52(3):183-94. PMID: 22086658. Su L, Liu G, Hao X, et al. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur J Cancer. 2011 Nov;47(16):2471-8. PMID: 21726997. Daidone F, Florio R, Rinaldo S, et al. In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed. Eur J Med Chem. 2011 May;46(5):1616-21. PMID: 21371789. Joerger M, Omlin A, Cerny T, et al. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets. 2010 Jan;11(1):37-47. PMID: 19839929. Blackwood E, Epler J, Yen I, et al. Combination drug scheduling defines a “window of opportunity” for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. Mol Cancer Ther. 2013 Oct;12(10):1968-1980. PMID: 23873850.